Table 4 Reports of miR-200 in ovarian cancer

200a/b/c

High expression in ovarian cancer samples

[7, 8, 10]

High expression correlated with decreased progression-free survival

[8]

Decreased in tumors with high β-tubulin III levels

[33]

200a

Increased in 43% of primary ovarian carcinomas, associated with high-grade and late-stage tumors

[9]

High expression correlated with recurrence free survival and, or, overall survival

[34, 35]

Increased tumour growth, targets p38α and modulates oxidative stress signature

[34]

Sensitized tumors to paclitaxel

[34]

200c

Targeted TUBB3 for degradation leading to increased paclitaxel sensitivity

[36]

Low levels associated with incomplete response to paclitaxel–carboplatin chemotherapy and recurrence

[33]

Decreased adhesion to basement membrane complex

[36]

Repressed ZEB1, decreased migration and invasion in HEY cells

[36]